Wolters Kluwer N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WTKWY research report →
Price Chart
About the company
Wolters Kluwer N. V. is an international enterprise specializing in the provision of professional information, advanced software solutions, and diverse services.
- CEO
- Stacey Caywood
- IPO
- 1999
- Employees
- 20,567
- HQ
- Alphen aan den Rijn, ZH, NL
Get TickerSpark's AI analysis on WTKWY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.63B
- P/E
- 11.96
- Fwd P/E
- 14.83
- PEG
- 0.50
- P/S
- 2.62
- P/B
- 16.91
- EV/EBITDA
- 9.91
- Div Yield
- 3.56%
- Gross Margin
- 74.07%
- Op Margin
- 25.60%
- Net Margin
- 21.86%
- ROE
- 153.62%
- ROIC
- 17.78%
Latest fiscal year · YoY change
- Revenue
- $6.13B+3.5%
- Gross Profit
- $4.50B+4.9%
- Op Income
- $1.48B
- Net Income
- $1.26B+16.4%
- EPS
- $5.44+19.8%
- OCF Growth
- -3.1%
- FCF Growth
- -2.2%
- 52W High
- $138.76
- 52W Low
- $63.22
- 50D MA
- $72.80
- 200D MA
- $84.35
- Beta
- 0.18
- RSI (14)
- 62
- Avg Volume
- 88.37K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Wolters Kluwer posted a solid first half with 5% organic growth, margin expansion, and strong AI rollout progress, while reaffirming full-year guidance.· August 5, 2026
- First-half revenue was EUR 3.033 billion; organic growth was 5% and 6% excluding print.
- Adjusted operating profit was EUR 893 million, up 10% in constant currencies, and the margin rose 100 bps to 29.4%.
- Diluted adjusted EPS increased 14% in constant currencies to EUR 2.83, and adjusted free cash flow rose 14% to EUR 533 million.
- Management reiterated full-year guidance for around 28% adjusted operating margin and high-single-digit diluted adjusted EPS growth in constant currencies.
- AI adoption was a major theme, with over 90% of U.S. Enterprise Edition UpToDate customers signed up for Expert AI and around 250 accounting firms subscribing to one or more CCH Axcess AI modules.
First-half 2026 revenues were EUR 3.033 billion, down 1% reported due to currency but up 4% in constant currencies and up 5% organically. Adjusted operating profit was EUR 893 million, up 10% in constant currencies; the adjusted operating margin expanded 100 basis points to 29.4%. First-half diluted adjusted EPS was EUR 2.83, up 14% in constant currencies, and adjusted free cash flow was EUR 533 million, up 14% in constant currencies. For the full year, management reiterated guidance for another year of good organic growth, further margin increase, high-single-digit growth in diluted adjusted EPS in constant currencies, and an adjusted operating margin of approximately 28%.
Stacey Caywood said the company had a good start to the year and emphasized that subscription renewals are strong across the group. Her strategic focus was on accelerating advanced AI innovation, embedding AI into core platforms, and using partnerships and workflow integrations to deepen customer adoption. She highlighted broad rollout progress in Health, Tax & Accounting, and Legal & Regulatory, while noting that recent acquisitions and partnerships are already contributing to growth.
Kevin Entricken highlighted the hard numbers behind the first-half performance: EUR 3.033 billion in revenue, EUR 893 million in adjusted operating profit, 29.4% margin, EUR 2.83 diluted adjusted EPS, and EUR 533 million of adjusted free cash flow. He said the margin gain was helped by operational gearing, efficiency programs, and the FRR divestiture, but that product development spending is expected to rise from 11% of revenues in the first half to 12% to 13% for the full year, weighted to the second half. He also noted net debt of about EUR 4 billion, a 2.0x net debt-to-EBITDA ratio, and a commitment to both the progressive dividend and share repurchases, including EUR 215 million of buybacks in the first half.
Analysts focused heavily on AI monetization, the pace of adoption inside customer bases, and how much pricing power AI features could add. Management said Expert AI is bundled into Enterprise Edition subscriptions in Health, with monetization expected mainly through renewals, price increases, and add-on modules over time; they declined to quantify user-level adoption or immediate pricing uplift. Questions also probed second-half margin pressure, and Kevin said higher product development and token costs will weigh, though AI token costs remain a small part of the cost base. On legal and tax, management said second-half growth should improve as Brightflag becomes organic and Libra contributes later, while ProSystem-to-Axcess migration is now over the halfway mark.
The call showed broad-based organic growth across all five divisions, with particularly strong momentum in cloud software, renewals, and AI-related offerings. Management sounded confident that AI is becoming embedded in customer workflows, citing over 90% U.S. Enterprise Edition sign-up for Expert AI, rapid adoption of Libra, and early traction in CCH Axcess agentic modules.
Management acknowledged second-half margin pressure from stepped-up product development spending and some rising AI-related token costs, even if those costs are described as small. They also flagged softer areas: slower Enablon sales cycles tied to Middle East geopolitical uncertainty, subdued transaction activity in Financial & Corporate Compliance due to higher rates, and competitive pressure in individual UpToDate usage from AI-native clinical tools and free medical chatbots.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.0%
- Shares Outstanding
- 225.88M
- Float Shares
- 225.88M
Congressional trading
Senate and House stock disclosures for WTKWY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Aug 3, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Held by 6 ETFs
Biggest fund positions in WTKWY by dollar value.
Our WTKWY coverage
Recent articles, reports, and earnings notes.
No research on WTKWY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WTKWY report →Wolters Kluwer Study Identifies Seven-Year High in Subpoena Volumes
businesswire.com · Aug 19
Wolters Kluwer NV (OTCMKTS:WTKWY) Short Interest Up 148.5% in July
defenseworld.net · Aug 14
Wolters Kluwer Brings Trusted Medi-Span Medication Intelligence to Growing Veterinary Drug Market
businesswire.com · Aug 11
Health System Adoption of Wolters Kluwer UpToDate Expert AI Now Reaching Approximately 2,500 U.S. Hospitals and Health Systems
businesswire.com · Aug 6
Wolters Kluwer N.V. (WTKWY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 5
Wolters Kluwer 2026 Half-Year Report
globenewswire.com · Aug 5
Wolters Kluwer to Help Rural Hospitals and FQHCs Access Top Drug Information and Patient Education Solutions Integrated With Epic
businesswire.com · Jul 30
Norway's health system adopts Wolters Kluwer UpToDate Enterprise Edition
businesswire.com · Jul 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.